Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Rhea-AI Summary

Marinus Pharmaceuticals, a leader in therapeutics for seizure disorders, announced its participation in several key investor and medical conferences in May and June. Events include the Citi Biotech Virtual Co-Panel on May 18, H.C. Wainwright Global Investment Conference available on demand starting May 24, and the Jefferies Global Healthcare Conference on June 9. Marinus will also attend the EILAT Conference from May 22-25 in Madrid and the Epilepsy Foundation Pipeline Conference on June 6. The company focuses on developing innovative treatments like Ganaxolone for both adults and children.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in the following investor and medical conferences in May and June:

Citi Biotech Virtual Co-Panel Day
May 18 at 3:30 p.m. ET.
This presentation will be closed to conference participants only.

H.C. Wainwright Global Investment Conference
Available on demand starting May 24 at 7:00 a.m. ET.
Webcast Link: https://journey.ct.events/view/f447a79f-2d56-40f1-9924-e6b53707d9c1

Jefferies Global Healthcare Conference
June 9 at 3:30 p.m. ET in New York, N.Y.
Webcast Link: https://wsw.com/webcast/jeff240/mrns/1869600

16th EILAT Conference on New Antiepileptic Drugs and Devices
May 22 – 25 in Madrid, Spain
This event is closed to conference participants only.

Epilepsy Foundation Pipeline Conference
June 6 at 6:20 p.m. ET / 3:20 p.m. PT in Santa Clara, Calif.
This presentation will be closed to conference participants only.

About Marinus Pharmaceuticals
Marinus is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a neuroactive steroid GABA_A receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005448/en/

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

484-253-6792

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals, Inc.

FAQ

What conferences is Marinus Pharmaceuticals participating in during May and June 2023?

Marinus Pharmaceuticals is participating in the Citi Biotech Virtual Co-Panel Day on May 18, H.C. Wainwright Global Investment Conference starting May 24, Jefferies Global Healthcare Conference on June 9, EILAT Conference from May 22-25 in Madrid, and Epilepsy Foundation Pipeline Conference on June 6.

When is the H.C. Wainwright Global Investment Conference?

The H.C. Wainwright Global Investment Conference is available on demand starting May 24, 2023, at 7:00 a.m. ET.

What is Ganaxolone developed by Marinus Pharmaceuticals?

Ganaxolone is a neuroactive steroid GABA_A receptor modulator being developed by Marinus Pharmaceuticals to treat seizure disorders in both IV and oral formulations.

Where will the Jefferies Global Healthcare Conference take place?

The Jefferies Global Healthcare Conference will take place in New York, N.Y., on June 9, 2023, at 3:30 p.m. ET.

What is Marinus Pharmaceuticals' focus as a company?

Marinus Pharmaceuticals is focused on developing innovative therapeutics specifically for treating seizure disorders.